<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01308632</url>
  </required_header>
  <id_info>
    <org_study_id>GENOM-007</org_study_id>
    <nct_id>NCT01308632</nct_id>
  </id_info>
  <brief_title>Metronomic Temozolamide in Patients With Recurrent Glioblastoma</brief_title>
  <official_title>PHASE I-II TRIAL OF METRONOMIC TEMOZOLAMIDE WITH INTERMITTENT INTENSIFICATION AND IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Investigación en Neurooncología</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Español de Investigación en Neurooncología</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Indication:&#xD;
&#xD;
      Subjects with glioblastoma at first relapse after surgery, radiotherapy and first-line&#xD;
      temozolomide (TMZ).&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        1. Phase I endpoint:&#xD;
&#xD;
           - To determine the maximum tolerated dose (MTD) of CPT-11 administered on days 8 and 22&#xD;
           in combination with a fixed, continuous, and metronomic regimen of TMZ, given in 28-day&#xD;
           cycles.&#xD;
&#xD;
        2. Phase II endpoints:&#xD;
&#xD;
      Primary endpoint: Progression-free survival at 6 months. Secondary endpoints: Response rate,&#xD;
      toxicity profile, overall survival.&#xD;
&#xD;
      Complementary studies:&#xD;
&#xD;
      To assess the effect of treatment on plasma concentration of thrombospondin-1 (TSP1), soluble&#xD;
      VEGF receptor 1 (sVEGF-1) and VEGF-A, and their correlation with clinical outcome.&#xD;
&#xD;
        -  To assess the correlation between immunohistochemical expression of PTEN and MGMT&#xD;
           proteins, and clinical outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: Open label, phase I - II trial. Phase I trial: TMZ will be administered in a&#xD;
      fixed schedule as follows:&#xD;
&#xD;
      TMZ&#xD;
&#xD;
        -  50 mg/m2/day divided in three daily doses (approx. 17 mg/m2/8 hours) on days 1-7, 9-21,&#xD;
           and 23-28.&#xD;
&#xD;
        -  100 mg/m2 in a morning single dose on days 8 and 22&#xD;
&#xD;
      CPT-11 starting dose:&#xD;
&#xD;
      .100 mg/m2 on days 8 and 22, administered 3 to 6 hours after TMZ.(Level 1).One cycle = 28&#xD;
      days. CPT-11 will be escalated in successive cohorts of 3 patients as follows: 115, 130, 145,&#xD;
      160 mg/m2 .&#xD;
&#xD;
      Three patients will be treated at dose level 1. If there is no DLT, 3 new patients will be&#xD;
      treated at dose level 2, and so on. If 1 or 2 of the 3 patients initially recruited at each&#xD;
      treatment level experience DLT, 3 additional patients will be included at the same level. If&#xD;
      DLT is registered in less than 3 of the 6 patients treated at this level, 3 new patients will&#xD;
      be included in the next dose level. If 3 or more of the 6 patients experience DLT, the phase&#xD;
      I trial will be closed and the previous treatment level will be chosen for the phase II&#xD;
      trial. If all 3 initial patients at one level experience DLT, the previous dose level will be&#xD;
      used in the phase II trial.&#xD;
&#xD;
      If DLT is found at dose level 1, phase I trial will be re-started at level -2 (70 mg/m2 ) and&#xD;
      -1 (85 mg/m2).&#xD;
&#xD;
      Definition of DLT:&#xD;
&#xD;
        -  Absolute neutrophil count (ANC) &lt; 500/ μl &gt; 7 days&#xD;
&#xD;
        -  Platelet count &lt; 25000/ μl&#xD;
&#xD;
        -  A delay in starting a new cycle by &gt; 7 days to allow recovery from toxicity (ANC ≥ 1500/&#xD;
           μl and platelet count ≥ 100000/ μl&#xD;
&#xD;
        -  Febrile Neutropenia&#xD;
&#xD;
        -  Non-haematological toxicity grade 3-4, except alopecia and nausea/vomiting or diarrhea&#xD;
           without adequate prophylaxis or treatment.&#xD;
&#xD;
      Phase II trial: Patients will receive the treatment schedule at the dose level stated in the&#xD;
      phase I study. Treatment will be maintained until progression or excessive toxicity.&#xD;
&#xD;
      Patient evaluation: A physical examination, blood count, and basic biochemistry assessment&#xD;
      will be performed within 3 weeks before treatment and at each study visit. Tumor recurrence&#xD;
      or progression has to be demonstrated by MRI scan performed within 3 weeks before the first&#xD;
      treatment course and after every second course of chemotherapy. The assessment of tumor&#xD;
      response will be based on criteria defined by Macdonald et al. Study visits will be performed&#xD;
      on days 1, 8, 15 and 22 of first and second treatment course, and on days 8 and 22&#xD;
      thereafter, if no significant toxicity has been observed.&#xD;
&#xD;
      Complementary studies: The immunohistochemical expression of PTEN and MGMT will be assessed&#xD;
      in paraffin sections of tumor tissue of all patients.&#xD;
&#xD;
      Blood samples for enzyme immunoassay of TSP1, sVEGFR-1 and VEGF-A will be collected within 3&#xD;
      weeks before treatment, after course 1 and every 3 treatment courses thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of the treatment (Phase I)</measure>
    <time_frame>every patient should receive at least one cycle ( 28 days)</time_frame>
    <description>To determine the maximum tolerated dose (MTD) of CPT-11 administered on days 8 and 22 in combination with a fixed, continuous and metronomic regimen of TMZ, given in 28-days cycles to use the Recommended Dose in phase II</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (Phase II)</measure>
    <time_frame>Since the initial of the treatment until the patient progression</time_frame>
    <description>The time the patient is not in progression, since the beginning of the treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the toxicity of the treatment</measure>
    <time_frame>the patients will be followed until disease progression</time_frame>
    <description>Toxicity Profile (in phase II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival at 6 months</measure>
    <time_frame>6 months since the pacient is included in the trial</time_frame>
    <description>Progression-free survival at 6 months (Phase I)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>the patients will be followed until death</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Temozolamide, irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I trial:&#xD;
TMZ will be administered in a fixed schedule as follows:&#xD;
TMZ 50 mg/m2/day divided in three daily doses (approx. 17 mg/m2/8 hours) on days 1-7, 9-21, and 23-28.&#xD;
100 mg/m2 in a morning single dose on days 8 and 22&#xD;
CPT-11 starting dose:&#xD;
100 mg/m2 on days 8 and 22, administered 3 to 6 hours after TMZ. (Level 1)&#xD;
One cycle = 28 days&#xD;
CPT-11 will be escalated in successive cohorts of 3 patients as follows: 115, 130, 145, 160 mg/m2 .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolamide, irinotecan</intervention_name>
    <description>Phase I trial:&#xD;
TMZ will be administered in a fixed schedule as follows:&#xD;
TMZ 50 mg/m2/day divided in three daily doses (approx. 17 mg/m2/8 hours) on days 1-7, 9-21, and 23-28.&#xD;
100 mg/m2 in a morning single dose on days 8 and 22&#xD;
CPT-11 starting dose:&#xD;
100 mg/m2 on days 8 and 22, administered 3 to 6 hours after TMZ. (Level 1)&#xD;
One cycle = 28 days&#xD;
CPT-11 will be escalated in successive cohorts of 3 patients as follows: 115, 130, 145, 160 mg/m2 .</description>
    <arm_group_label>Temozolamide, irinotecan</arm_group_label>
    <other_name>CPT-11</other_name>
    <other_name>Campto</other_name>
    <other_name>Irinotecan</other_name>
    <other_name>Temozolamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients &gt; 18 years old&#xD;
&#xD;
          2. Histological confirmed GB at first relapse, assessed by MRI scan, after surgical&#xD;
             resection or biopsy, radiotherapy, and first-line chemotherapy with TMZ. A TMZ&#xD;
             treatment duration of at least 3 months is required. Previous chemotherapy with CPT-11&#xD;
             is not allowed.&#xD;
&#xD;
          3. Karnofsky performance status ≥ 70.&#xD;
&#xD;
          4. ANC ≥ 1500/ μl, platelet count ≥ 100000/ μl, haemoglobin &gt; 10 g/dl, serum creatinine&#xD;
             and total bilirubin &lt; 1.5 times the upper limit of laboratory normal, transaminases &lt;&#xD;
             3.0 times the upper limit of laboratory normal.&#xD;
&#xD;
          5. Stable or descending corticosteroid dose ≥ 72 hours before baseline MRI and study&#xD;
             treatment.&#xD;
&#xD;
          6. Life expectancy greater than 3 months&#xD;
&#xD;
          7. Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or breastfeeding.&#xD;
&#xD;
          2. Neurological impairment that precludes comprehension or treatment administration&#xD;
&#xD;
          3. Vomiting or other condition that interfere with oral administration of TMZ&#xD;
&#xD;
          4. Previous or concurrent malignancy, excluding basal cell carcinomas or in situ cervical&#xD;
             cancer.&#xD;
&#xD;
          5. Concurrent disease that could interfere with treatment&#xD;
&#xD;
          6. Concurrent treatment with enzyme-inducing drugs. Patients under enzyme-inducing&#xD;
             anticonvulsants should discontinue treatment at least one week before study treatment&#xD;
             and begin a new anti-epileptic treatment with non enzyme-inducing drugs if indicated.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reynés Gaspar, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Fe de Valencia</affiliation>
  </overall_official>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>January 24, 2011</study_first_submitted>
  <study_first_submitted_qc>March 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2011</study_first_posted>
  <last_update_submitted>March 2, 2011</last_update_submitted>
  <last_update_submitted_qc>March 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Grupo Español de Investigación en Neurooncología,</name_title>
    <organization>GEINO</organization>
  </responsible_party>
  <keyword>glioblastoma</keyword>
  <keyword>temozolamide</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>TMZ</keyword>
  <keyword>irinotecan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

